BUSINESS WIRE
EDEN PRAIRIE, Minn., Apr 24, 2008 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification and drug delivery technologies to the healthcare
industry, announced today that two posters and one paper will be
presented at the 2008 Association for Research in Vision and
Ophthalmology (ARVO) Meeting being held April 27 - May 1, 2008 in Fort
Lauderdale, Florida. All of the data presented in these sessions are
related to the drug delivery platform technologies currently under
development at SurModics.
"We are pleased to be presenting the results from our ongoing drug
delivery development programs at this year's ARVO Meeting," said Paul
Lopez, president of SurModics' Ophthalmology Division. "SurModics'
continues to make significant progress with innovative drug delivery
systems for the treatment of back-of-the eye diseases. The continued
clinical development of the I-vation(TM) TA intravitreal implant
product and our work with biodegradable drug delivery systems for both
large and small molecules will be highlighted at this meeting."
The poster # 3501/A590 entitled I-vation(TM) TA: 15-Month Clinical
Results of the Phase I Safety and Preliminary Efficacy Study, is to be
presented on Tuesday, April 29, 2008 at 3:00 PM (EDT) and includes 15-
and 18-month clinical data results from the Phase I clinical trial
which is evaluating the I-vation intravitreal implant with
triamcinoclone acetonide in patients with Diabetic Macular Edema
(DME).
The poster # 3183/D916 entitled Long-Term Protein Stability in a
Biodegradable Polysaccharide Drug Delivery Implant, to be presented
Tuesday, April 29, 2008 at 11:15 AM (EDT), presents data from a
pre-clinical study designed to demonstrate stabilization of bioactive
protein in a degradable polysaccharide matrix system designed for
sustained, controlled release of therapeutic agents into the vitreous.
The paper #5004 entitled Hydrophobic Biodegradable Polysaccharide
Implant for Controlled Drug Delivery, to be presented Thursday, May 1,
2008 at 8:45 AM (EDT), highlights results from a study demonstrating
controlled in-vitro and in-vivo sustained release of a small molecule
from a biodegradable polysaccharide ocular implant.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification and
drug delivery technologies to the healthcare industry. SurModics
partners with the world's foremost medical device, pharmaceutical and
life science companies to develop and commercialize innovative
products that result in improved patient outcomes. Core offerings
include: drug delivery technologies (coatings, microparticles, and
implants); surface modification coating technologies that impart
lubricity, prohealing, and biocompatibility capabilities; and
components for in vitro diagnostic test kits and specialized surfaces
for cell culture and microarrays. Collaborative efforts include a
sustained drug delivery system in human trials for treatment of
retinal disease and the drug delivery polymer matrix on the
first-to-market drug-eluting coronary stent. SurModics is
headquartered in Eden Prairie, Minnesota and its Brookwood
Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more
information about the company, visit www.surmodics.com. The content of
SurModics' website is not part of this release or part of any filings
the company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements
that are not historical or current facts, including statements about
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties,
and important factors could cause actual results to differ materially
from those anticipated, including the following: (1) realizing the
full potential benefits of the company's agreement with Merck & Co.,
Inc. requires the development of new products and applications of
technology; (2) costs or difficulties relating to the integration of
the businesses of Brookwood Pharmaceuticals and BioFX Laboratories
with SurModics' business may be greater than expected and may
adversely affect the company's results of operations and financial
condition; (3) developments in the regulatory environment, as well as
market and economic conditions, and our reliance on third parties, may
adversely affect our business operations and profitability, and the
company's ability to achieve our fiscal 2008 corporate goals and to
realize the potential of our pipeline; and (4) other factors
identified under "Risk Factors" in Part I, Item 1A of our Annual
Report on Form 10-K for the fiscal year ended September 30, 2007, and
updated in our subsequent reports filed with the SEC. These reports
are available in the Investors section of our website at
www.surmodics.com and at the SEC website at www.sec.gov.
Forward-looking statements speak only as of the date they are made,
and we undertake no obligation to update them in light of new
information or future events.